Literature DB >> 21406981

Chemoprophylaxis for HIV prevention: new opportunities and new questions.

Kenneth H Mayer1, Kartik K Venkatesh.   

Abstract

Growing data suggest that antiretrovirals can be used as an effective means of HIV prevention. This article reviews the current status and future clinical prospects of utilizing antiretroviral chemoprophylaxis before and after high-risk HIV exposure to prevent HIV transmission. The discussion about using antiretrovirals as a means of primary HIV prevention has moved to the forefront of public health discourse because of a growing evidence base, the increased tolerability of the medications, the decreased cost, the ever-expanding formulary, and the limitations of other approaches.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21406981      PMCID： PMC3075435          DOI： 10.1097/QAI.0b013e3181fbcb4c

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN： 1525-4135            Impact factor:   3.731


  36 in total

Review 1.  Antiretroviral drug concentrations in semen of HIV-1 infected men.

Authors:  S Taylor; A S Pereira
Journal:  Sex Transm Infect       Date:  2001-02       Impact factor: 3.519

2.  Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.

Authors:  Quarraisha Abdool Karim; Salim S Abdool Karim; Janet A Frohlich; Anneke C Grobler; Cheryl Baxter; Leila E Mansoor; Ayesha B M Kharsany; Sengeziwe Sibeko; Koleka P Mlisana; Zaheen Omar; Tanuja N Gengiah; Silvia Maarschalk; Natasha Arulappan; Mukelisiwe Mlotshwa; Lynn Morris; Douglas Taylor
Journal:  Science       Date:  2010-07-19       Impact factor: 47.728

3.  Nucleoside analogues achieve high concentrations in seminal plasma: relationship between drug concentration and virus burden.

Authors:  A S Pereira; A D Kashuba; S A Fiscus; J E Hall; R R Tidwell; L Troiani; J A Dunn; J J Eron; M S Cohen
Journal:  J Infect Dis       Date:  1999-12       Impact factor: 5.226

4.  Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: limited knowledge and experience but potential for increased utilization after education.

Authors:  Matthew J Mimiaga; Patricia Case; Carey V Johnson; Steven A Safren; Kenneth H Mayer
Journal:  J Acquir Immune Defic Syndr       Date:  2009-01-01       Impact factor: 3.731

5.  Highly active antiretroviral treatment for the prevention of HIV transmission.

Authors:  Reuben Granich; Siobhan Crowley; Marco Vitoria; Ying-Ru Lo; Yves Souteyrand; Christopher Dye; Charlie Gilks; Teguest Guerma; Kevin M De Cock; Brian Williams
Journal:  J Int AIDS Soc       Date:  2010-01-12       Impact factor: 5.396

6.  A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group.

Authors:  D M Cardo; D H Culver; C A Ciesielski; P U Srivastava; R Marcus; D Abiteboul; J Heptonstall; G Ippolito; F Lot; P S McKibben; D M Bell
Journal:  N Engl J Med       Date:  1997-11-20       Impact factor: 91.245

Review 7.  Behavioural strategies to reduce HIV transmission: how to make them work better.

Authors:  Thomas J Coates; Linda Richter; Carlos Caceres
Journal:  Lancet       Date:  2008-08-05       Impact factor: 79.321

8.  Tenofovir DF plus lamivudine or emtricitabine for nonoccupational postexposure prophylaxis (NPEP) in a Boston Community Health Center.

Authors:  Kenneth H Mayer; Matthew J Mimiaga; Daniel Cohen; Chris Grasso; Ronn Bill; Rodney Van Derwarker; Alvan Fisher
Journal:  J Acquir Immune Defic Syndr       Date:  2008-04-01       Impact factor: 3.731

Review 9.  Two drugs or three? Balancing efficacy, toxicity, and resistance in postexposure prophylaxis for occupational exposure to HIV.

Authors:  Ingrid V Bassett; Kenneth A Freedberg; Rochelle P Walensky
Journal:  Clin Infect Dis       Date:  2004-07-16       Impact factor: 9.079

10.  Resistance of HIV-1 to antiretroviral agents in blood and seminal plasma: implications for transmission.

Authors:  J J Eron; P L Vernazza; D M Johnston; F Seillier-Moiseiwitsch; T M Alcorn; S A Fiscus; M S Cohen
Journal:  AIDS       Date:  1998-10-22       Impact factor: 4.177
View more
  5 in total

1.  Passing the baton: Community-based ethnography to design a randomized clinical trial on the effectiveness of oral pre-exposure prophylaxis for HIV prevention among Black men who have sex with men.

Authors:  Jonathan Garcia; Paul W Colson; Caroline Parker; Jennifer S Hirsch
Journal:  Contemp Clin Trials       Date:  2015-11-09       Impact factor: 2.226

2.  Preclinical evaluation of the HIV-1 fusion inhibitor L'644 as a potential candidate microbicide.

Authors:  Sarah Harman; Carolina Herrera; Naomi Armanasco; Jeremy Nuttall; Robin J Shattock
Journal:  Antimicrob Agents Chemother       Date:  2012-02-13       Impact factor: 5.191

3.  Experience in international clinical research: the HIV Prevention Trials Network.

Authors:  Nirupama Deshmane Sista; Quarraisha Abdool Karim; Kathy Hinson; Deborah Donnell; Susan H Eshleman; Sten H Vermund
Journal:  Clin Investig (Lond)       Date:  2011-12

4.  Acceptability of pre-exposure prophylaxis among men who have sex with men and transgender women in Northern Thailand.

Authors:  Daniel Yang; Chonlisa Chariyalertsak; Antika Wongthanee; Surinda Kawichai; Kriengkrai Yotruean; Pongpun Saokhieo; Thomas Guadamuz; Voravit Suwanvanichkij; Chris Beyrer; Suwat Chariyalertsak
Journal:  PLoS One       Date:  2013-10-08       Impact factor: 3.240

5.  Cell-to-cell transmission of HIV-1 from provirus-activated cells to resting naïve and memory human primary CD4 T cells is highly efficient and requires CD4 and F-actin but not chemokine receptors.

Authors:  Jie Lan; Wei Li; Richard Yu; Fahim Syed; Qigui Yu
Journal:  J Med Virol       Date:  2022-07-23       Impact factor: 20.693
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.